Perifosine — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	2	41	—	—	1999-08
Multiple Myeloma	Phase3	Phase 3	1	4	—	—	2005-12
Non-Hodgkin Lymphoma	Phase3	Phase 3	1	7	—	—	2005-12
Leukemia	Phase2	Phase 2	0	4	—	—	1999-08

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIK3CA E542K1
Perifosine + Temsirolimus

Clinical trials

Trials with this intervention (41)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–41 of 41 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00053781	Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma	completed	Phase 2	18	NCIC Clinical Trials GroupNETWORK	1	Aug 4, 2023	clinicaltrials
NCT00053794	Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma	completed	Phase 2